Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
Lower heart failure and chronic kidney disease risks associated with sodium‐glucose cotransporter‐2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases
I. Komuro,T. Kadowaki,3 Authors,T. Yajima
TLDR
To examine heart failure and chronic kidney disease risks reduction associated with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) compared to other glucose‐lowering drugs (oGLD) in the early stage of type 2 diabetes patients without established cardiovascular or renal diseases (CVRD‐free T2D).
Abstract
To examine heart failure (HF) and chronic kidney disease (CKD) risks reduction associated with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) compared to other glucose‐lowering drugs (oGLD) in the early stage of type 2 diabetes patients without established cardiovascular or renal diseases (CVRD‐free T2D).